Skip survey header

9756 AIMS primer posttest

Posttest

1. Vanessa is a 29-year-old African American patient with RRMS who has been treated with IFNβ-1a (30 µg, IM, weekly) since her diagnosis 2 years ago. She has shown no signs of breakthrough disease clinically or on MRI, and has experienced few difficulties with tolerability. At her most recent follow-up appointment, she inquired about treatment options with a less frequent dosing schedule. Which disease modifying therapy would be most appropriate for Vanessa? *This question is required.
2. In addition to monthly CBC with differential, which of the following is part of recommended monitoring following treatment initiation for patients treated with alemtuzumab? *This question is required.
3. Mark is a 45-year-old white male with newly-diagnosed primary progressive MS (PPMS) based on progressive onset starting about 13 months ago; periventricular, symptomatic T2 lesions noted on MRI, and oligoclonal bands found in CSF. Which of the following would you consider as initial treatment for Mark based on FDA approval status for his MS type? *This question is required.
4. Which of these therapies in development for RRMS has been shown in animal models to promote myelin repair? *This question is required.
5. Which of the following sphingosine-1-phosphate receptor (S1PR) agonists in development for treatment of RRMS is selective only for the S1PR subtype 1? *This question is required.
6. Which of the following concepts focuses specifically on fostering communication among all members of the multidisciplinary health care team? *This question is required.
7. A number of biomarkers are under investigation for monitoring MS disease activity or worsening. Of the following candidates, which has shown promise in terms of correlating with MRI and the Expanded Disability Status Scale (EDSS) measures of disease severity? *This question is required.
8. Multidisciplinary, comprehensive care for patients with MS should include a primary care provider to help prevent or manage comorbid conditions. According to the North American Research Committee on Multiple Sclerosis (NARCOMS) registry, which of the following physical comorbidity was most frequently reported by patients with MS? *This question is required.
0%